Transcenta is based in Hong Kong, China. It has raised $100M in total funding. Latest round: Series B.
Transcenta funding overview
Transcenta is based in Hong Kong, China. Transcenta has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in January 2020. The round record for Transcenta runs through 2020; nothing later has been disclosed. Investors on record include CR-CP Life Science Fund, Fortune Capital, Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group, Lilly Asia Ventures and 5 others. 11 distinct backers are named across the disclosed rounds.
Transcenta at a glance
Total raised
$100M
Latest round
Series B
Latest round date
January 2020
Headquarters
Hong Kong, China
Notable investors
CR-CP Life Science Fund, Fortune Capital, Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group, Lilly Asia Ventures, Temasek, Hillhouse Capital
Frequently asked about Transcenta funding
How much has Transcenta raised?
Transcenta has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Transcenta?
CR-CP Life Science Fund, Fortune Capital, Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group, Lilly Asia Ventures are named among the investors backing Transcenta.
What was the latest Transcenta funding round?
The most recent disclosed round is a Series B, announced in January 2020.
Where is Transcenta based?
Transcenta is based in Hong Kong, China.
When did Transcenta last raise?
The last disclosed Transcenta round closed in January 2020 at Series B.
Transcenta totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Hong Kong below to benchmark round size and investor mix.
